Clinical Study Of FND And CHOP Chemotherapy For Indolent Non-Hodgkin Lymphoma Patients

Objective:To investigate the efficacy and safety of FND chemotherapy for indolent non-Hodgkin lymphoma compared with CHOP regimen. Method:Between January 2000 and December 2009, 125 patients with pathologically confirmed indolent non-Hodgkin lymphomawere included into the study. 61 of the indolent lymphoma patients were received FND regimen (fludarabine 25mg/m~2IV d1-3, mitoxantrone 10mg/m~2IV d1, dexamethasone 40mg PO d1-5, every 4 weeks ). 64 of the indolent lymphoma patients were received CHOP regimen(750 mg/ m~2 IV d1, doxorubicin 25 mg/ m~2 IV d1 and vincristine 1. 4 mg/ m~2 IV d1,8, and prednisone 40 mg/ m~2 Po d1~5).Result:The overall response(OR)was78.7% in FND group,while was 55% in CHOP group; for the patients ,the OR in FND group was higher than in CHOP group obstructively (P< 0. 05). The 5-year overall survival rates of patients were 93.2%and 83.6% ( Pï¹¥0.05).Conclusions:FND regimen is more effective in the treatmentof advanced indolent non-Hodgkin lymphoma than the CHOP regimens. The toxic reactions of the 2 groups are similar.